Does Cosentyx Weaken Response to Vaccines?
Cosentyx (secukinumab), an IL-17A inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, reduces vaccine-induced immunity in adults. It impairs antibody responses to non-live vaccines like Tdap (tetanus, diphtheria, pertussis) and influenza, with studies showing 20-40% lower seroprotection rates compared to placebo.[1][2]
Impact on Specific Vaccines
- Inactivated or subunit vaccines: In phase 3 trials, 57% of Cosentyx-treated adults achieved protective Tdap titers vs. 79% on placebo. Influenza vaccine response dropped similarly, with geometric mean antibody titers halved.[1]
- COVID-19 vaccines: Real-world data indicate lower neutralizing antibody levels post-mRNA vaccination in Cosentyx users, though clinical infection rates remain comparable due to T-cell preservation.[3]
- Live vaccines: Contraindicated due to immunosuppression risk; avoid during treatment and for 4-6 weeks after stopping.[1]
How Long Do Effects Last?
Impaired responses occur within weeks of starting Cosentyx and persist during ongoing therapy (every 4 weeks dosing). Post-discontinuation, immunity recovers in 3-6 months, aligning with IL-17 pathway normalization.[2]
Pneumococcal and Other Routine Shots
Cosentyx lowers seroconversion to pneumococcal vaccines (PCV13) by 15-25%, prompting recommendations for boosters or higher doses in adults.[1] Shingles (zoster) vaccine response is also blunted, increasing outbreak risk.[4]
T-Cell vs. Antibody Effects
Cosentyx mainly hits B-cell/antibody production via IL-17 blockade, sparing T-cell responses, which supports some cellular immunity to vaccines.[2][3]
Clinical Recommendations for Adults
Guidelines advise vaccinating before starting Cosentyx. During treatment, use non-live vaccines anyway but monitor titers; consider dose adjustments or revaccination off-drug.[1][5] No increased severe infection risk from vaccination itself.
[1]: Cosentyx Prescribing Information (Novartis)
[2]: Bagel et al., J Am Acad Dermatol (2019) – SECURE trial data
[3]: Winthrop et al., Ann Rheum Dis (2022) – COVID vaccine study in IL-17 inhibitors
[4]: Leung et al., Rheumatology (2021) – Zoster vaccine in biologics
[5]: EULAR/ACR Guidelines on Vaccination in Rheumatic Diseases (2023)